BCL2L1 and neoplasm: Subject to clinical validation, this information may be useful in deciding when to utilize a radiosensitizer like a Bcl-xL inhibitor in women with TNBC at high risk or locoregional recurrence based on clinicopathologic features (large tumor, lymph node involvement, high-grade disease, etc.).